ELAPRASE® (idursulfase) is a prescription medicine for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II), which was approved by the Food and Drug Administration (FDA) in 2006.
The active substance in ELAPRASE is an enzyme that breaks down glycosaminoglycans (GAG). Due to an enzyme deficiency, these GAGs accumulate inside people with Hunter syndrome, causing the signs and symptoms of the condition. For example, the build-up of GAGs within organs such as the liver and spleen results in enlarged organ size.
ELAPRASE is an “enzyme replacement therapy” (ERT) because it is a formulation of the enzyme called iduronate-2-sulfatase (I2S) which is missing or deficient in people with Hunter syndrome.
ELAPRASE is a purified form of the I2S enzyme produced by recombinant DNA technology in a human cell line.
ELAPRASE is the first and only FDA-approved ERT for Hunter syndrome.
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.